A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma

作者：He, Hong-Ling; Yao, Wan-Xia^*

来源：Bioscience Reports, 2017, 37(6): BSR20170827.

DOI：10.1042/BSR20170827

• INTERFERON-ALPHA
• DOUBLE-BLIND
• OPEN-LABEL
• SUNITINIB
• SORAFENIB
• CABOZANTINIB
• EVEROLIMUS
• PAZOPANIB
• AXITINIB
• CANCER

The network meta-analysis was conducted to compare the short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma (RCC). We initially searched databases for randomized controlled trials (RCTs) on different single-drug targeted therapies in treating RCC. The meta-analysis combined the direct and indirect evidence to calculate the pooled odds ratios (OR) and draw surface under the cumulative ranking curves (SUCRA). A total of 14 eligible RCTs were ultimately selected. The partial response (PR) of Cabozantinib in the treatment of RCC was better than Sunitinib (OR = 2.7, 95% CI = 1.0-7.8), Everolimus (OR = 8.1, 95% CI = 3.1-25.0), and Temsirolimus (OR = 4.8, 95% CI = 1.0-31.0); the overall response rate (ORR) of Cabozantinib was better than Sorafenib, Sunitinib, Everolimus, and Temsirolimus (OR = 5.5, 95% CI = 1.1-27.0; OR = 2.6, 95% CI = 1.1-6.6; OR = 8.3, 95% CI = 3.5-20.0; OR = 5.7, 95% CI = 1.3-28.0 respectively). In addition, as for complete response (CR), PR, stable disease (SD), progressive disease (PD), ORR, and disease control rate (DCR), Cabozantinib had the best short-term efficacy among nine single-drug targeted therapies in the treatment of RCC (CR: 50.3%; PR: 93.6%; SD: 75.1%; PD: 68.0%; ORR: 95.5%; DCR: 73.2%); while Everolimus had the worst short-term efficacy (CR: 33.6%; PR: 22.3%; SD: 78.0%; PD: 35.9%; ORR: 22.9%; DCR: 19.9%). Our network meta-analysis indicated that Cabozantinib might have better short-term efficacy than other regimens in the treatment of RCC, while Everolimus might have poor short-term efficacy.

• 出版日期2017-12-22
• 单位西安交通大学